<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287806</url>
  </required_header>
  <id_info>
    <org_study_id>Uilis-china</org_study_id>
    <nct_id>NCT01287806</nct_id>
  </id_info>
  <brief_title>Ulinastatin in Inhalation Lung Injury</brief_title>
  <official_title>Multicenter,Randomized,Parallel Assignment,Blank Control Study of Ulinastatin in Inhalation Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Beijing PLA Military Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and effect of ulinastatin in inhalation
      lung injury patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>until death or discharge from hospital, data reviewed every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of mechanical ventilation</measure>
    <time_frame>from admission to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay</measure>
    <time_frame>until death or discharge from hospital, data reviewed every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stays</measure>
    <time_frame>until death or discharge from hospital, data reviewed every 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood inflammatory mediator</measure>
    <time_frame>0days,5days and 10days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchoscopy morphological evaluation</measure>
    <time_frame>0days,5days and 10days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Inhalation Injury</condition>
  <arm_group>
    <arm_group_label>blank control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ulinastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ulinastatin</intervention_name>
    <description>Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days</description>
    <arm_group_label>ulinastatin group</arm_group_label>
    <other_name>brand name: noan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>blank group</intervention_name>
    <description>standard treatment</description>
    <arm_group_label>blank control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe inhalation lung injury

          -  Within 48hours after inhalation injury

          -  Age 18 to 70 years old

          -  Burned area not more than 70% TBSA

          -  Signed the informed consent form

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Allergy for ulinastatin

          -  Received an investigational drug or device within 90 days prior to entering study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sheng zhiyong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Hospitals affiliated to the China PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia chiyu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospitals affiliated to the China PLA General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xia zhaofan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pang yizhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen tunhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Jinan PLA Military Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhu jinmin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Beijing PLA Military Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liu yi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Lanzhou PLA Military Region</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cui xiaolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaonin People's Armed Police Corps Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng guanyu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>187 Central Hospital of the Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lu qinjun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>251 Central Hospital of the Chinese PLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shi shengfu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>322 Central Hospital of the Chinese PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheng zhiyong, MD</last_name>
    <phone>86-13910008199</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia chiyu, MD</last_name>
    <email>JCY304@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>304 hospital of PLA</name>
      <address>
        <city>Beijin</city>
        <state>Beijin</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheng zhiyong, MD</last_name>
      <phone>86-13910008199</phone>
    </contact>
    <contact_backup>
      <last_name>Jia chiyu, MD</last_name>
      <email>JCY304@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jia chiyu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>January 31, 2011</last_update_submitted>
  <last_update_submitted_qc>January 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sheng Zhiyong</name_title>
    <organization>General Hospital of the People's Liberation Army</organization>
  </responsible_party>
  <keyword>ulinastatin</keyword>
  <keyword>inhalation injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

